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Six cases of acute hepatitis C related to computed to-
mography scanning with contrast were identiﬁ  ed in 3 hospi-
tals. A patient with chronic hepatitis C had been subjected 
to the same procedure immediately before each patient in 
whom acute infection developed. Viral molecular analysis 
showed identity between isolates from patients with acute 
and chronic hepatitis C.
T
he most common mechanism involved in transmission 
of hepatitis C virus (HCV) is exposure to contaminated 
blood; sharing of syringes between drug users is currently 
the most frequent factor. However, in 40% of cases, the 
mechanism cannot be identiﬁ  ed, and nosocomial transmis-
sion has an increasingly important role (1). 
In recent years, transmission of HCV from an infected 
patient to a susceptible person during various healthcare-re-
lated procedures has been reported (2,3). The risk of trans-
mission depends on the mechanism responsible, as well as 
on the prevalence of infected persons. Thus, in addition to 
use of shared vials for administration of heparin (4), physi-
ological saline solution (5–7) or anesthetics (8,9), proce-
dures carried out with contaminated equipment (10,11) or 
inappropriate practices of health personnel (12) have been 
proposed as mechanisms of nosocomial transmission. Mo-
lecular analysis of HCV has permitted comparison of dif-
ferent viral sequences to conﬁ  rm transmission.
Hepatitis C infection is a mandatory reportable disease 
in Spain and is reported as a suspected infection as soon 
as it is clinically diagnosed. In Barcelona, after  initial re-
porting of a case of hepatitis C,  an epidemiologic survey 
is conducted by trained personnel from the epidemiologic 
service to identify possible sources of infection (sexual 
or household contact with an HCV case, use of multidose 
medications, transfusions, surgical interventions or other 
invasive procedures during their hospital stay) and to im-
plement appropriate control measures. The aim of the pres-
ent study was to describe several cases of nosocomial HCV 
transmission affecting patients in which the identiﬁ  ed pos-
sible source of transmission was a computed tomography 
(CT) scan with contrast in different hospitals in Barcelona 
in 2004.
The Study
From August through November 2004, 6 cases of 
acute hepatitis C associated with a CT scan with contrast 
were diagnosed in 2 public hospitals and 1 private diag-
nostic center. Only 1 was detected by active case ﬁ  nding. 
Three cases were women and 3 were men (ages 29, 47, 55, 
57, 58 and 61 years, respectively). All but 1 had symptoms 
compatible with acute hepatitis with dates of onset from 
July 8 to September 18, 2004. All had increased serum 
transaminase levels, positive serologic results for hepatitis 
C, and HCV RNA detected by reverse transcription–PCR. 
All cases were investigated and other sources of transmis-
sion were ruled out; all participants were outpatients with 
appointments and did not undergo any speciﬁ  c tests before 
or after the scan. None shared any equipment or locations 
with carriers, none received multidose injectable medica-
tions or contaminated saline ﬂ  ushes, and none shared other 
exposures during their CT procedure. All patients had re-
cently undergone a CT scan with contrast: 3 patients on 
June 11, and 1 each on June 25, June 29, and August 9. An 
epidemiologic study was conducted that deﬁ  ned a hepatitis 
C case as a person who satisﬁ  ed  the following 3 criteria: 1) 
diagnosis of acute hepatitis C according to the case deﬁ  ni-
tion of the Catalan Surveillance System (13); 2) having un-
dergone a CT scan with contrast in the 6 months before di-
agnosis; and 3) the case was detected from August through 
November 2004. All persons tested with the same multi-
dose contrast equipment; a reported case were screened to 
detect possible HCV carriers.
 Transmission was demonstrated by similarity of HCV 
sequences isolated from acute hepatitis cases with those 
sequences isolated from carriers with chronic hepatitis C 
by using phylogenetic analysis. Brieﬂ  y, glycoprotein E2 
coding sequence (nt 1301–1808 encompassing hypervari-
able region 1) was ampliﬁ  ed by nested PCR as previously 
described (3,4). This analysis was performed in 2 laborato-
ries: Hospital Clinic and Hospital Vall d’Hebron.
Four independent carrier-case events were identiﬁ  ed, 
as shown in Table 1. Three cases on the same day were 
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ately after the carrier, and 1 case (asymptomatic) was not 
consecutive (only 1 person between cases 2 and 3), result-
ing in a secondary attack rate of 60.0% (95% conﬁ  dence 
interval [CI) 17.04–92.74) (Table 2) In the other 3 events, 
the case was scanned immediately after the carrier; global 
secondary attack rate was 26.08% (95% CI 11.08–48.68). 
The ﬁ  rst event was probably caused by a carrier viral load 
greater than that of the other events. All cases involved the 
immediately prior scan of an HCV carrier and they clus-
tered in the same node, on the basis of 1,000 resamplings, 
with a value ≈100%; some part of the contrast injection 
equipment had been used for all cases (Figure 1). All trans-
mission events resulted in well-deﬁ  ned, highly supported 
monophyletic groups when samples involved in the out-
break were analyzed (>95%). Conversely, sequences from 
unrelated samples did not show bootstrap support (<70%) 
(3,14). Epidemiologically unrelated strains from the same 
area were included in the analysis.
In the hospital where 2 episodes of transmission oc-
curred on different days, a retrospective study was carried 
out to eliminate other cases of transmission of HCV among 
the 1,486 patients subjected to a CT scan with contrast 
after a patient with known HCV infection from May 15 
through August 15, 2004. This period included the expo-
sure period of both transmissions. This analysis yielded 71 
infectious HCV carriers who had a scan in which equip-
ment was shared with noninfected patients. Of the 71 pair-
ings of carriers-susceptible patients, 57 susceptible persons 
were tested for antibodies to HCV, 10 had died, and 4 could 
not be located. No new cases were identiﬁ  ed, resulting in a 
frequency of HCV transmission of 3.5 95% CI 0.61–13.16) 
per 100 carriers for whom equipment was shared during 
the 3-month period. The consecutively scanned patient was 
HCV negative. 
Characteristics of the equipment used for contrast injec-
tion in all settings were investigated, along with the proce-
dure used, to identify critical points for virus transmission.   
The equipment (Figure 2) included a contrast injector with 
automatic load from a 500-mL bottle that was shared by >4 
persons. The contrast solution arrived in a preﬁ  lled bottle 
(manufactured by different pharmaceutical companies) that 
is loaded through a connection tube into the injector. We 
investigated this procedure and did not detect any risk of 
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Table 1. Characteristics of 6 acute hepatitis C infections attributable to computed tomography (CT) scan with contrast* 
Characteristic Event 1 Event 2 Event 3 Event 4
Hospital/center A A A A B C
Carrier no.  1 1 1 2 3 4
  CT scan date/time 2004 Jun 11,
3:00 PM
2004 Jun 11,
3:00 PM
2004 Jun 11, 
3:00 PM
2004 Jun 25,
9:05 AM
2004 Jun 29,
11:00 AM
2004 Aug 9,
5:44 PM
Case-patient no.   1 2 3 4 5 6
 Sex F M F F M M
 Age,  y 47 58 57 55 29 61
  CT scan date/time  2004 Jun 11,
3:50 PM
2004 Jun 11,
4:16 PM
2004 Jun 11, 
5:17 PM
2004 Jun 25,
9:37 AM
2004 Jun 29,
11:29 AM
2004 Aug 9,
6:43 PM
  Symptom onset 2004 Aug 7  2004 Aug 8 Asymptomatic 2004 Aug 4 2004 Aug 12 2004 Aug 18
  Diagnosis 2004 Aug 9 2004 Aug 12 2004 Oct 15 2004 Aug 14 2004 Aug 18 2004 Aug 28
 Diagnostic  test Seroconversion,
anti-HCV, RNA 
HCV
Seroconversion,
anti-HCV, RNA 
HCV
Seroconversion,
anti-HCV, RNA 
HCV
Anti-HCV, RNA 
HCV
Seroconversion,
anti-HCV, RNA 
HCV
Seroconversion,
anti-HCV, RNA 
HCV
  Date reported 2004 Aug 20 2004 Aug 20 NA 2004 Aug 20 2004 Nov 22 2004 Nov 5
 Genotype 1b,  phylogenetic 
identity with 
carrier 1
1b, phylogenetic 
identity with 
carrier 1
1b, phylogenetic 
identity with 
carrier 1
1b, phylogenetic 
identity with 
carrier 2
1b, phylogenetic 
identity with 
carrier 3
1b,
phylogenetic 
identity with 
carrier 4
*The 2 hospitals and 1 diagnostic center from which case-patients were identified are designated as A, B, and C. Anti-HCV, antibody to hepatitis C virus; 
NA, not applicable. 
Table 2. Transmission of hepatitis C during computed tomography scan with contrast* 
2004
Characteristic Jun 11 Jun 25 Jun 29 Aug 9
No. patients scanned after carrier, sharing same 
equipment
51 15 2
N o .  c a s e s  o f  t r a n s m i s s i o n 3111
Time between carrier scan and case scan 2 h 17 min 32 min 29 min 59 min
Hospital A A B C
Secondary attack rate, % (95% CI) 60 (17.04–92.74) 9.09 (0.47–42.88) 20 (1.05–70.12) 50 (2.66–97.33)
Syringe replacement Every 8 h Every 8 h <8 h >24 h
Disconnection procedure with risk of transmission Present Present Present Present
*CI, confidence interval. Transmission of Hepatitis C and Computed Tomography     
blood contamination. Replacement of the injector varied 
among hospitals, and use time ranged from 8 hours to sev-
eral days. All equipment was connected to the patient by 
the intravenous route through an extension tube ﬁ  tted with 
a nonreturn valve. This extension tube was the only part 
of the equipment that was changed for each patient. One 
maneuver involving risk of blood contamination of the ex-
tension tube was identiﬁ  ed in all hospitals. Contamination 
could have occurred through the hands of health personnel 
manipulating the extension tube by disconnecting the tube 
from the patient ﬁ  rst and then from the equipment without 
changing gloves between these manipulations. Other fac-
tors that could have contributed to transmission were lack 
of written instructions to guarantee proper practice; train-
ing of new technicians by experienced technicians, which 
may perpetuate errors; and work overload, with a maxi-
mum time of <9 min available for each CT scan (from the 
time the patient enters until he or she leaves), which could 
lead to a lower level of standard precautions. 
Two sets of control measures were used. The ﬁ  rst set, 
which emphasized appropriate use of health products and 
stressed the importance of following manufacturer’s in-
structions (a contrast injection syringe for each patient), 
was obtained from the Agencia Española del Medicamento. 
The second set included a written protocol for performing 
a CT scan with contrast and procedures to avoid transmis-
sion of infectious diseases. A follow up of infected patients 
was ensured, as well as preventive treatment. This will be 
reported by the responsible team in the future.
Conclusions
Our study had several limitations that should be tak-
en into account. First, our study was a case series and we 
only described cases and their potential sources of infec-
tion. Second, although we carried out active case ﬁ  nding, 
we must assume that other related cases were not detected. 
Detection of this problem in 3 hospitals in the same city 
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Figure 1. Phylogenetic tree of the partial 
glycoprotein E2 sequences of hepatitis C 
virus from patients investigated in 2 public 
hospitals and 1 private diagnostic center and 
control samples retrieved from Hospital Clinic 
and Hospital Vall d’Hebron in Barcelona, 
Spain. GenBank accession nos.: DQ682391, 
DQ682392, DQ682393, DQ682394, DQ682376, 
DQ682377, EU380670, EU380671, EU380672, 
EU380673, EU380674, EU380675. Branch 
lengths are drawn to scale. Only bootstrap 
values >70% are shown. 
Figure 2. Equipment for contrast administration in computed 
tomography scan.within a short period suggests that CT scan with contrast 
could be responsible for an unknown number of prevent-
able HCV infections in industrialized countries if infection 
control procedures are not strictly applied.
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